Lead Product(s) : SB-007
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SpliceBio Doses First Patient in Phase 1/2 ASTRA Trial of SB-007 for Stargardt
Details : SB-007 is a protein splicing dual AAV gene therapy that delivers the full-length ABCA4 gene. It is being evaluated for the treatment of stargardt disease.
Product Name : SB-007
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : SB-007
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AXO-AAV-GM1
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Sio Gene Therapies
Deal Size : Undisclosed
Deal Type : Partnership
Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership
Details : Axovant will have access to manufacturing resources for Axovant’s AAV-based gene therapy programs, AXO-AAV-GM1 for GM1 gangliosidosis and AXO-AAV-GM2 for GM2 gangliosidosis with sufficient capacity to support ongoing development and eventual commercial...
Product Name : AXO-AAV-GM1
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 15, 2020
Lead Product(s) : AXO-AAV-GM1
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Sio Gene Therapies
Deal Size : Undisclosed
Deal Type : Partnership